451 related articles for article (PubMed ID: 29907598)
21. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.
Sim J; Kim H; Hyeon J; Choi Y; Han J
J Korean Med Sci; 2018 Apr; 33(15):e123. PubMed ID: 29629521
[TBL] [Abstract][Full Text] [Related]
22. Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Landi L; Cappuzzo F
Expert Rev Clin Pharmacol; 2016; 9(2):203-14. PubMed ID: 26582431
[TBL] [Abstract][Full Text] [Related]
23. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
[TBL] [Abstract][Full Text] [Related]
24. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
25. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
Ni Z; Zhang TC
J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
[TBL] [Abstract][Full Text] [Related]
26. [Ceritinib in the treatment of an adult patient with advanced neuroblastoma positive to the somatic activating mutation of ALK F1174L.].
Soto Parra HJ; Noto L; Aiello MM
Recenti Prog Med; 2020 Dec; 111(12):58e-62e. PubMed ID: 33362184
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.
Cho BC; Obermannova R; Bearz A; McKeage M; Kim DW; Batra U; Borra G; Orlov S; Kim SW; Geater SL; Postmus PE; Laurie SA; Park K; Yang CT; Ardizzoni A; Bettini AC; de Castro G; Kiertsman F; Chen Z; Lau YY; Viraswami-Appanna K; Passos VQ; Dziadziuszko R
J Thorac Oncol; 2019 Jul; 14(7):1255-1265. PubMed ID: 30851442
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of ceritinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
Tian W; Zhang P; Yuan Y; Deng XH; Yue R; Ge XZ
J Clin Pharm Ther; 2020 Aug; 45(4):743-754. PubMed ID: 32369239
[TBL] [Abstract][Full Text] [Related]
29. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
Crinò L; Ahn MJ; De Marinis F; Groen HJ; Wakelee H; Hida T; Mok T; Spigel D; Felip E; Nishio M; Scagliotti G; Branle F; Emeremni C; Quadrigli M; Zhang J; Shaw AT
J Clin Oncol; 2016 Aug; 34(24):2866-73. PubMed ID: 27432917
[TBL] [Abstract][Full Text] [Related]
30. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
31. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma.
Subbiah V; Kuravi S; Ganguly S; Welch DR; Vivian CJ; Mushtaq MU; Hegde A; Iyer S; Behrang A; Ali SM; Madison RW; Venstrom JM; Jensen RA; McGuirk JP; Amin HM; Balusu R
ESMO Open; 2021 Aug; 6(4):100172. PubMed ID: 34242968
[TBL] [Abstract][Full Text] [Related]
32. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
33. A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.
Kodityal S; Elvin JA; Squillace R; Agarwal N; Miller VA; Ali SM; Klempner SJ; Ou SH
Lung Cancer; 2016 Feb; 92():19-21. PubMed ID: 26775591
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis.
Koshikawa K; Terada J; Abe M; Iwasawa S; Sakayori M; Yoshioka K; Hirasawa Y; Kasai H; Kawasaki Y; Tsushima K; Tatsumi K
Thorac Cancer; 2020 Jun; 11(6):1495-1502. PubMed ID: 32237210
[TBL] [Abstract][Full Text] [Related]
35. SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L; Wang HQ; Singh M; Fordjour P; Shaw KX; Yoda S; Kerr G; Yu K; Liang J; Cao Y; Chen Y; Lawrence MS; Langenbucher A; Gainor JF; Friboulet L; Dagogo-Jack I; Myers DT; Labrot E; Ruddy D; Parks M; Lee D; DiCecca RH; Moody S; Hao H; Mohseni M; LaMarche M; Williams J; Hoffmaster K; Caponigro G; Shaw AT; Hata AN; Benes CH; Li F; Engelman JA
Nat Med; 2018 May; 24(4):512-517. PubMed ID: 29505033
[TBL] [Abstract][Full Text] [Related]
36. Structural basis for drug resistance mechanisms against anaplastic lymphoma kinase.
Goyal S; Jamal S; Shanker A; Grover A
J Cell Biochem; 2019 Jan; 120(1):768-777. PubMed ID: 30161279
[TBL] [Abstract][Full Text] [Related]
37. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
38. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Kang J; Chen HJ; Zhang XC; Su J; Zhou Q; Tu HY; Wang Z; Wang BC; Zhong WZ; Yang XN; Chen ZH; Ding Y; Wu X; Wang M; Fu JG; Yang Z; Zhang X; Shao YW; Wu YL; Yang JJ
Thorac Cancer; 2018 Sep; 9(9):1093-1103. PubMed ID: 29978950
[TBL] [Abstract][Full Text] [Related]
40. Ceritinib (LDK378): a potent alternative to crizotinib for ALK-rearranged non-small-cell lung cancer.
Li S; Qi X; Huang Y; Liu D; Zhou F; Zhou C
Clin Lung Cancer; 2015 Mar; 16(2):86-91. PubMed ID: 25458559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
